Pacific Biosciences' Q1 Revenues Better Than Anticipated, Down Sequentially | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday first-quarter revenues of $10 million, beating Wall Street's consensus estimate of $7.1 million.

The revenues compared to $270,000 in revenue for the first quarter of 2011, before the firm launched its PacBio RS system. The Q1 2012 revenues compare to fourth-quarter 2011 revenues of $12.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.